Pluri (PLUR) Return on Capital Employed (2011 - 2025)
Pluri (PLUR) posted quarterly Return on Capital Employed of 11734.43% for Q4 2025, up 1181009.0% year-over-year from N/an in Q4 2024, and up 2120.88% quarter-over-quarter from 580.66% in Q3 2025.
Pluri (PLUR) Return on Capital Employed (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Return on Capital Employed for 15 consecutive years, with 11734.43% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 1181009.0% year-over-year to 11734.43%; the TTM figure through Dec 2025 stood at 11734.43% (up 1181009.0% YoY), while the FY2025 annual figure was 327.22%, down 27279.0% from the prior year.
- Return on Capital Employed rose to 11734.43% in Q4 2025 per PLUR's latest filing, from 580.66% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11734.43% in Q4 2025 and bottomed at 580.66% in Q3 2025.
- Historically, Return on Capital Employed has averaged 482.18% across 5 years, with a median of 65.97% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 1181009 bps in 2025 and fell as far as 51386 bps in 2025.
- Pluri's Return on Capital Employed stood at 70.05% in 2021, then gained by 14 bps to 60.41% in 2022, then slipped by 4 bps to 62.91% in 2023, then dropped by 20 bps to 75.66% in 2024, then soared by 15610 bps to 11734.43% in 2025.
- Business Quant data shows PLUR's Return on Capital Employed at 11734.43% in Q4 2025, 580.66% in Q3 2025, and 387.9% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 11,734.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11,734.43% |
| Sep 30, 2025 | -580.66% |
| Jun 30, 2025 | -387.90% |
| Mar 31, 2025 | -75.94% |
| Dec 31, 2024 | -75.66% |
| Sep 30, 2024 | -66.80% |
| Jun 30, 2024 | -66.13% |
| Mar 31, 2024 | -65.80% |
| Dec 31, 2023 | -62.91% |
| Sep 30, 2023 | -59.29% |
| Jun 30, 2023 | -56.88% |
| Mar 31, 2023 | -56.13% |
| Dec 31, 2022 | -60.41% |
| Sep 30, 2022 | -62.95% |
| Jun 30, 2022 | -62.30% |
| Mar 31, 2022 | -65.39% |
| Dec 31, 2021 | -70.05% |
| Sep 30, 2021 | -68.13% |
| Jun 30, 2021 | -67.64% |
| Mar 31, 2021 | -79.84% |